Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Early Treatment Outcomes of SARS-Cov-2 with Ivermectin, Nitazoxanide and Acetylsalicylic Acid in 2 Nursing Homes During The COVID-19 Pandemic in Cali, Colombia

Corral et al., Global Journal of Aging & Geriatric Research, doi:10.33552/GJAGR.2024.03.000557
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19ivm.org
Retrospective 475 nursing home residents showing low mortality with early treatment using ivermectin, nitazoxanide, and acetylsalicylic acid. All residents were treated when the first positive cases were identified. 87 residents tested positive for SARS-CoV-2 over the study period and only one resident died of a heart attack at 30 days (1.1% mortality for SARS-CoV-2 positive residents, 0.2% for all residents receiving treatment). 71 residents remained in the nursing homes, 13 were hospitalized in the internal ward, 2 were referred to higher level care, and none were referred to the ICU.
Study covers ivermectin, nitazoxanide, and aspirin.
Corral et al., 12 Apr 2024, Colombia, peer-reviewed, 9 authors.
This PaperIvermectinAll
Early Treatment Outcomes of SARS-Cov-2 with Ivermectin, Nitazoxanide and Acetylsalicylic Acid in 2 Nursing Homes During The COVID-19 Pandemic in Cali, Colombia
Full Raúl H Corral, José Oscar Gutiérrez, Alejandro Varela, Bertha López, Héctor Cortes, José Mauricio Ocampo, Francisco Tamayo, Alvaro Martínez, Alberto Concha Eastman
doi:10.33552/GJAGR.2024.03.000557
Introduction: The high lethality of COVID-19 among older adults and especially in nursing homes led to the implementation of early treatment for residents in 2 geriatric institutions in Cali, Colombia, where outbreaks of SARS-CoV-2 occurred at different times of the epidemic. Only one of the 475 residents, who was positive for the infection, died of a heart attack. Objectives: To provide data regarding the early initiation of pharmacological treatment and interdisciplinary monitoring of patients who were RT-PCR-positive or antigen-positive for SARS-CoV-2, as well as to their close contacts. Also, we look for less referrals to hospitals of high-level complexity or to intensive care units, and to contribute to reducing mortality in older adults in nursing homes. Methods: This is an evaluation of early pharmacological treatment administered to 475 older adults residing in 2 nursing homes, where outbreaks of SARS-CoV-2 were identified by the authorities of each institution. SARS-CoV-2 RT-PCR or antigen tests were performed for all residents. The Rockwood Clinical Frailty Scale (CFS) was taken into account, and the NEWS-2 National Early Warning Score was used to determine which cases should be managed at the institution and which should be referred to a hospital with a higher level of complexity. Interdisciplinary follow-up was carried out by the medical, nursing, psychology and social work staff at the institutions for 30 days. The pharmacological treatment administered to all residents was ivermectin (600 mcg/kg) on days 1 and 7; nitazoxanide (500 mg), BD for 6 days; and acetylsalicylic acid (100 mg) interday, on days 1, 3, 5, and 7.
Conflict of Interest No Conflict of Interest.
References
Akinbami, Chan, Vuong, Sami, Lewis, severe acute respiratory syndrome coronavirus 2 seropositivity among healthcare personnel in hospitals and nursing homes, Rhode Island, USA, July-August 2020, Emerg Infect Dis
Barnett, Grabowski, Nursing homes are ground zero for COVID-19 Pandemic, JAMA Heal Forum
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Canzano, Brambilla, Porro, Cosentino, Tortorici, Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients, JACC Basic to Transl Sci
Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and COVID-19: Keeping rigor in times of urgency, Am J Trop Med Hyg
Comas-Herrera, Zalakain, Lemmon, Henderson, Litwin, Mortality associated with COVID-19 outbreaks in care homes: early international evidence -Resources to support community and institutional Long-Term Care responses to COVID-19
Elguea, Prado, Barradas, Implementación de una escala de gravedad para la activación del equipo de respuesta rápida: NEWS 2, Med Crit
Gorges, Konetzka, Staffing levels and COVID-19 cases and outbreaks in U.S. nursing homes, J Am Geriatr Soc
Gorial, Mashhadani, Sayaly, Dakhil, Almashhadani, Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial)
Guerrero, Bravo, Muñoz, Grillo, Guerrero, COVID-19: The ivermectin African enigma [Internet], Colomb Med
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
Hewitt, Carter, Vilches-Moraga, Quinn, Braude, The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study, Lancet Public Health
Hägg, Jylhävä, Wang, Xu, Metzner, Age, frailty, and comorbidity as prognostic factors for short-term outcomes in patients with coronavirus disease 2019 in geriatric care, J Am Med Dir Assoc
Kelleni, Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management, Pharmacol Res
Lester, Holahan, Siskind, Healy, Policy recommendations regarding skilled nursing facility management of Coronavirus 19 (COVID-19): Lessons from New York State, J Am Med Dir Assoc
Martins-Filho, Barreto-Alves, Fakhouri, Potential role for nitazoxanide in treating SARS-CoV-2 infection, J Physiol Lung Cell Mol Physiol
Ops, Raúl, Corral, José, Gutiérrez et al., Early Treatment Outcomes of SARS-Cov-2 with Ivermectin, Nitazoxanide and Acetylsalicylic Acid in 2 Nursing Homes During The COVID-19 Pandemic in Cali, Colombia, Glob J Aging Geriatr Res
Rajter, Sherman, Fatteh, Vogel, Sacks, Ivermectin in COVID-19 study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19
Raúl, Corral, José, Gutiérrez, Varela et al., Early Treatment Outcomes of SARS-Cov-2 with Ivermectin, Nitazoxanide and Acetylsalicylic Acid in 2 Nursing Homes During The COVID-19 Pandemic in Cali, Colombia, Glob J Aging Geriatr Res
Rocco, Silva, Cruz, Junior, Tierno, Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial, Eur Respir J
Rockwood, Song, Macknight, Bergman, Hogan, A global clinical measure of fitness and frailty in elderly people, CMAJ
Smet, Mellaerts, Vandewinckele, Lybeert, Frans, Frailty and mortality in hospitalized older adults with COVID-19: Retrospective observational study, J Am Med Dir Assoc
Su, Mcdonnell, Li, Why is COVID-19 more deadly to nursing home residents?, QJM An Int J Med
Tjia, Rothman, Kiely, Shaffer, Holmes, Daily medication use in nursing home residents with advanced dementia, J Am Geriatr Soc
Whitworth, Hay, Nicholas, Morgan, Maude, Coagulation abnormalities and ivermectin, Ann Trop Med Parasitol
Zhao, Huang, Huang, Mortality in older patients with COVID-19, J Am Geriatr Soc
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit